<?xml version="1.0" encoding="UTF-8"?>
<p>This is a potent, broadly neutralizing investigational human IgG1 mAb targeting a highly conserved stalk region of the HA protein. MEDI8852 has been reported to effectively neutralize all known influenza A HA subtypes (
 <xref rid="ref77" ref-type="bibr">Kallewaard et al., 2016</xref>). Preclinical studies in animal models have shown efficacy in protecting against H5N1 influenza virus lethal challenges when used alone or in combination with oseltamivir (
 <xref rid="ref114" ref-type="bibr">Paules et al., 2017</xref>). A phase 2a study (NCT02603952) to evaluate the safety of MEDI8852 in adults with acute, uncomplicated influenza was recently concluded and results demonstrated an acceptable safety profile in this group of patients. In 2016, MEDI8852 received Fast Track designation by the FDA that allows the drug an expedite development and review (
 <xref rid="ref5" ref-type="bibr">Ali et al., 2018</xref>).
</p>
